Miniaturization and characterization of patient derived hepatocellular carcinoma tumor organoid cultures for cancer drug discovery applications
Patient derived tumor organoid (PDTO) models retain the structural, morphological, genetic, and clonal heterogeneity of the original tumors. The ability to efficiently generate, expand, and biobank PDTOs has the potential to make the clinical diversity of cancer accessible for personalized medicine...
Saved in:
Main Authors: | David A. Close, Paul A. Johnston |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-01-01
|
Series: | SLAS Discovery |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2472555224000637 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Personalising glioblastoma medicine: explant organoid applications, challenges and future perspectives
by: Niclas Skarne, et al.
Published: (2025-01-01) -
Application of organoids in drug screening of gynecological malignant tumors
by: JIANG Yuanyuan, WEI Wenfei, WU Jingya, LI Huawen
Published: (2024-11-01) -
Biomaterial-assisted organoid technology for disease modeling and drug screening
by: Yunyuan Shao, et al.
Published: (2025-02-01) -
Preliminary study of utilizing a patient derived tumor spheroid model to augment precision therapy in metastatic brain tumors
by: Chun-Jen Chang, et al.
Published: (2024-12-01) -
Cholangiocyte organoids for disease, cancer, and regenerative medicine
by: Munemasa Nagao, et al.
Published: (2025-03-01)